Applied DNA Q1 revenues $5.3M (+26% YoY); operating loss narrows to $1.2M

BNB PLUS CORP.

2023-Q1 EPS reported -$0.30 revenue$5,262,752

Total revenues $5.3M vs $4.2M in prior-year period; clinical lab service rev $4.5M (+41% YoY).
Gross profit $2.4M (45% margin) vs $1.1M (27%), driven by higher testing volumes and cost management.
Operating loss $1.2M vs $4.7M loss a year ago; Adjusted EBITDA -$1.1M vs -$2.7M.
Cash $12.9M at Dec 31, 2022; 7.3M warrants outstanding with potential proceeds of ~$26.6M.
cGMP facility build-out initiated within HQ; PGx validation package to be filed with NYSDOH.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

BNB PLUS CORP. reported first quarter of fiscal 2023, ended December 31, 2022 results: revenue $5.3 million.

Period: first quarter of fiscal 2023, ended December 31, 2022
Revenue: $5.3 million
Result: reported results

Exact text from the filing

Applied DNA Reports First Quarter Fiscal 2023 Financial Results - Total Revenues of $5.3 Million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-23-017571

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.